Dawn of a new era in olfactory regeneration: Pediatric stem cell therapy enters the era of long-term validation.

A recently published prospective study marks a breakthrough for congenital olfactory disorders in children. The study provides the first long-term, three-year follow-up data, robustly demonstrating the durable efficacy and safety of autologous nasal epithelial stem cell transplantation. This work reveals immense therapeutic potential for a condition traditionally considered untreatable. However, this milestone achievement also presents new challenges. To translate this pioneering therapy from a single-center success to a global standard, multicenter, controlled clinical trials must be initiated immediately. Only through rigorous validation can we ensure its widespread adoption and ultimately bring hope to millions of children worldwide.